These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 24357684)

  • 1. Central motor conduction time may predict response to fampridine in patients with multiple sclerosis.
    Zeller D; Reiners K; Bräuninger S; Buttmann M
    J Neurol Neurosurg Psychiatry; 2014 Jun; 85(6):707-9. PubMed ID: 24357684
    [No Abstract]   [Full Text] [Related]  

  • 2. [Fampridine and multiple sclerosis].
    Mathiesen HK; Sørensen PS
    Ugeskr Laeger; 2014 Jan; 176(3A):V06130416. PubMed ID: 25347174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained-release fampridine (4-aminopyridine) in multiple sclerosis: efficacy and impact on motor function.
    Rabadi MH; Kreymborg K; Vincent AS
    Drugs R D; 2013 Sep; 13(3):175-81. PubMed ID: 23873597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained release oral fampridine in the treatment of multiple sclerosis.
    Kachuck NJ
    Expert Opin Pharmacother; 2009 Aug; 10(12):2025-35. PubMed ID: 19586420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of modified-release fampridine on upper limb impairment in patients with Multiple Sclerosis.
    Marion S; Leonid C; Belinda B; Joanne D; Elise H; Leeanne C; Richard M
    Mult Scler Relat Disord; 2020 May; 40():101971. PubMed ID: 32062444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis.
    Mathiesen HK; Sorensen PS
    Expert Rev Neurother; 2013 Dec; 13(12):1309-17. PubMed ID: 24236901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
    Goodman AD; Brown TR; Krupp LB; Schapiro RT; Schwid SR; Cohen R; Marinucci LN; Blight AR;
    Lancet; 2009 Feb; 373(9665):732-8. PubMed ID: 19249634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-life experience with fampridine (Fampyra®) for patients with multiple sclerosis and gait disorders.
    Fragoso YD; Adoni T; Alves-Leon SV; Apostolos-Pereira SL; Barreira AA; Brooks JB; Claudino R; Correa EC; Ferreira ML; Finkelsztejn A; Finkelsztejn J; da Gama PD; Goncalves MV; Guerreiro CT; da Cunha Matta AP; Marques VD; Rizo Morales R; Parolin MF; de Castro Ribeiro M; Ribeiro TA; Ruocco HH; Sato H; Scherpenhuijzen S; Siquineli F; de Carvalho Sousa NA; Varela DL; Tauil CB; Winckler TC
    NeuroRehabilitation; 2016 Jun; 39(2):301-4. PubMed ID: 27372365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fampridine and real-life walking in multiple sclerosis: Low predictive value of clinical test for habitual short-term changes.
    Stellmann JP; Jlussi M; Neuhaus A; Lederer C; Daumer M; Heesen C
    J Neurol Sci; 2016 Sep; 368():318-25. PubMed ID: 27538657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting responsiveness to fampridine in gait-impaired patients with multiple sclerosis.
    Filli L; Werner J; Beyer G; Reuter K; Petersen JA; Weller M; Zörner B; Linnebank M
    Eur J Neurol; 2019 Feb; 26(2):281-289. PubMed ID: 30171655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Fampridine-PR (prolonged released 4-aminopyridine) on the manual functions of patients with Multiple Sclerosis.
    Savin Z; Lejbkowicz I; Glass-Marmor L; Lavi I; Rosenblum S; Miller A
    J Neurol Sci; 2016 Jan; 360():102-9. PubMed ID: 26723984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS).
    Preiningerova JL; Baumhackl U; Csepany T; Czaplinski A; Deisenhammer F; Derfuss T; Fabjan TH; Fazekas F; Fuchs S; Havrdova E; Ledinek AH; Illes Z; Jazbec SS; Klimova E; Komoly S; Kurca E; Linnebank M; Lisy L; Mares J; Prochazkova L; Csilla R; Szilasiova J; Stourac P; Talab R; Turcani P; Vachova M; Vecsei L; Vodusek D; Zapletalova O; Berger T
    CNS Neurosci Ther; 2013 May; 19(5):302-6. PubMed ID: 23607697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving function: a new treatment era for multiple sclerosis?
    Thompson A; Polman C
    Lancet; 2009 Feb; 373(9665):697-8. PubMed ID: 19249614
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis.
    Lugaresi A
    Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):295-306. PubMed ID: 25510833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of fampridine on axonal excitability in multiple sclerosis.
    Huynh W; Pickering H; Howells J; Murray J; Cormack C; Lin CS; Vucic S; Kiernan MC; Krishnan AV
    Clin Neurophysiol; 2016 Jul; 127(7):2636-42. PubMed ID: 27291883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of prolonged-release fampridine on multiple sclerosis-related gait impairments. A crossover, double-blinded, placebo-controlled study.
    Valet M; El Sankari S; Van Pesch V; Detrembleur C; Lejeune T; Stoquart G
    Clin Biomech (Bristol); 2021 Jun; 86():105382. PubMed ID: 34000628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern.
    Zörner B; Filli L; Reuter K; Kapitza S; Lörincz L; Sutter T; Weller D; Farkas M; Easthope CS; Czaplinski A; Weller M; Linnebank M
    Mult Scler; 2016 Oct; 22(11):1463-1475. PubMed ID: 26762672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early effect of dalfampridine in patients with MS: A multi-instrumental approach to better investigate responsiveness.
    Brambilla L; Rossi Sebastiano D; Aquino D; Torri Clerici V; Brenna G; Moscatelli M; Frangiamore R; Giovannetti AM; Antozzi C; Mantegazza R; Franceschetti S; Bruzzone MG; Erbetta A; Confalonieri P
    J Neurol Sci; 2016 Sep; 368():402-7. PubMed ID: 27538672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
    Filli L; Zörner B; Kapitza S; Reuter K; Lörincz L; Weller D; Sutter T; Killeen T; Gruber P; Petersen JA; Weller M; Linnebank M
    Neurology; 2017 Feb; 88(9):832-841. PubMed ID: 28148629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained-release fampridine for symptomatic treatment of multiple sclerosis.
    Korenke AR; Rivey MP; Allington DR
    Ann Pharmacother; 2008 Oct; 42(10):1458-65. PubMed ID: 18780812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.